HUE057795T2 - Adenoasszociált vírus terápiás szerek központi idegrendszerbe történõ bejuttatására - Google Patents

Adenoasszociált vírus terápiás szerek központi idegrendszerbe történõ bejuttatására

Info

Publication number
HUE057795T2
HUE057795T2 HUE16797013A HUE16797013A HUE057795T2 HU E057795 T2 HUE057795 T2 HU E057795T2 HU E16797013 A HUE16797013 A HU E16797013A HU E16797013 A HUE16797013 A HU E16797013A HU E057795 T2 HUE057795 T2 HU E057795T2
Authority
HU
Hungary
Prior art keywords
adeno
nervous system
central nervous
associated virus
therapeutic delivery
Prior art date
Application number
HUE16797013A
Other languages
English (en)
Inventor
R Scott Mcivor
Lalitha R Belur
Karen Kozarsky
Original Assignee
Regenxbio Inc
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57320277&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE057795(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regenxbio Inc, Univ Minnesota filed Critical Regenxbio Inc
Publication of HUE057795T2 publication Critical patent/HUE057795T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01076L-Iduronidase (3.2.1.76)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HUE16797013A 2015-05-15 2016-05-13 Adenoasszociált vírus terápiás szerek központi idegrendszerbe történõ bejuttatására HUE057795T2 (hu)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562162174P 2015-05-15 2015-05-15
US201562252055P 2015-11-06 2015-11-06
US201662301980P 2016-03-01 2016-03-01
US201662331156P 2016-05-03 2016-05-03

Publications (1)

Publication Number Publication Date
HUE057795T2 true HUE057795T2 (hu) 2022-06-28

Family

ID=57320277

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16797013A HUE057795T2 (hu) 2015-05-15 2016-05-13 Adenoasszociált vírus terápiás szerek központi idegrendszerbe történõ bejuttatására

Country Status (22)

Country Link
US (5) US20180289839A1 (hu)
EP (2) EP4000631A1 (hu)
JP (3) JP2018515615A (hu)
KR (2) KR102406615B1 (hu)
CN (1) CN108367055A (hu)
AU (2) AU2016263119B2 (hu)
BR (1) BR112017024519A2 (hu)
CA (1) CA2986252A1 (hu)
CY (1) CY1125229T1 (hu)
DK (1) DK3294323T3 (hu)
ES (1) ES2901766T3 (hu)
HK (2) HK1252871A1 (hu)
HR (1) HRP20220050T1 (hu)
HU (1) HUE057795T2 (hu)
LT (1) LT3294323T (hu)
MX (2) MX2017014443A (hu)
PL (1) PL3294323T3 (hu)
PT (1) PT3294323T (hu)
RS (1) RS63927B1 (hu)
RU (1) RU2751952C2 (hu)
SI (1) SI3294323T1 (hu)
WO (1) WO2016187017A1 (hu)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2971039B1 (en) 2013-03-14 2020-01-01 Immusoft Corporation Methods for in vitro memory b cell differentiation and transduction with vsv-g pseudotyped viral vectors
PL2984166T3 (pl) 2013-03-15 2021-01-11 The Trustees Of The University Of Pennsylvania Kompozycje do leczenia mpsi
BR112015028605A8 (pt) * 2013-05-15 2019-12-24 Univ Minnesota uso de uma composição e uso de um imunossupressor e uma composição
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
MX2017014443A (es) * 2015-05-15 2018-08-01 Univ Minnesota Adeno-asociado para administracion terapeutica al sistema nervioso central.
SG11201806270XA (en) 2016-02-03 2018-08-30 Univ Pennsylvania Gene therapy for treating mucopolysaccharidosis type i
CA3019427A1 (en) * 2016-04-15 2017-10-19 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
IL309808A (en) * 2016-11-15 2024-02-01 Univ Minnesota A method to improve neurological function in MPSI and MPSII and other neurological disorders
IL307936A (en) * 2017-04-14 2023-12-01 Regenxbio Inc Treatment for mucopolysaccharidosis 2 with the help of recombinant human iduronate-2 suplatase (ids) produced by human neuron or glial cells
CA3061048A1 (en) * 2017-04-27 2018-11-01 Immusoft Corporation B cells for in vivo delivery of therapeutic agents and dosages thereof
EP3676385A1 (en) 2017-07-06 2020-07-08 The Trustees of The University of Pennsylvania Aav9-mediated gene therapy for treating mucopolysaccharidosis type i
EP3684938A1 (en) 2017-09-22 2020-07-29 The Trustees of the University of Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
AU2018346105C1 (en) 2017-10-03 2023-10-12 Prevail Therapeutics, Inc. Gene therapies for lysosomal disorders
CN111542549A (zh) 2017-10-03 2020-08-14 普利维尔治疗公司 用于溶酶体障碍的基因疗法
US11807849B2 (en) 2017-10-03 2023-11-07 Prevail Therapeutics, Inc. Gene therapies for lysosomal disorders
CN111989396A (zh) 2017-11-30 2020-11-24 宾夕法尼亚州大学信托人 用于iiib型粘多糖贮积病的基因疗法
WO2019199841A1 (en) * 2018-04-09 2019-10-17 Cure Ahc, Inc. Aav-mediated delivery of atp1a3 genes to central nervous system
AU2019306236A1 (en) * 2018-07-18 2021-03-11 Regenxbio Inc. Treatment of mucopolysaccharidosis I with fully-human glycosylated human alpha-L-iduronidase (IDUS)
CA3136117A1 (en) 2019-04-10 2020-10-15 Prevail Therapeutics, Inc. Gene therapies for lysosomal disorders
AU2020270421A1 (en) * 2019-05-03 2021-11-18 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of metachromatic leukodystrophy
AU2020292256B2 (en) * 2019-06-10 2023-01-19 Homology Medicines, Inc. Adeno-associated virus compositions for ARSA gene transfer and methods of use thereof
KR20220112283A (ko) 2019-12-10 2022-08-10 다케다 야쿠힌 고교 가부시키가이샤 Hunter 질환 치료용 아데노-연합된 바이러스 벡터
US20230310654A1 (en) * 2020-08-10 2023-10-05 Prevail Therapeutics, Inc. Gene therapies for lysosomal disorders
WO2022121860A1 (en) * 2020-12-07 2022-06-16 East China University Of Science And Technology Methods and kits for inducing immunotolerance to gene delivering target vehicle
EP4284335A1 (en) 2021-02-01 2023-12-06 RegenxBio Inc. Gene therapy for neuronal ceroid lipofuscinoses
CA3209611A1 (en) 2021-02-10 2022-08-18 Regenxbio Inc. Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids)
WO2022212616A1 (en) * 2021-04-01 2022-10-06 The University Of North Carolina At Chapel Hill Aav-ids vectors for treatment of mucopolysaccharidosis ii

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
AU688428B2 (en) 1993-11-09 1998-03-12 Johns Hopkins University, The Generation of high titers of recombinant AAV vectors
ES2220923T3 (es) 1993-11-09 2004-12-16 Medical College Of Ohio Lineas celulares estables capaces de expresar el gen de replicacion del virus adeno-asociado.
EP0796339A1 (en) 1994-12-06 1997-09-24 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant aav vectors
US5656785A (en) 1995-08-07 1997-08-12 The Charles Stark Draper Laboratory, Inc. Micromechanical contact load force sensor for sensing magnitude and distribution of loads and tool employing micromechanical contact load force sensor
JP4397972B2 (ja) 1996-11-19 2010-01-13 サージックス コーポレイション 過渡電圧保護素子およびその製造方法
CA2270285A1 (en) 1996-12-18 1998-06-25 Targeted Genetics Corporation Aav split-packaging genes and cell lines comprising such genes for use in the production of recombinant aav vectors
EP1915986A1 (en) 2006-10-23 2008-04-30 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Lipid growth factor formulations
ES2634118T3 (es) * 2009-02-11 2017-09-26 The University Of North Carolina At Chapel Hill Vectores de virus modificados y métodos para fabricar y utilizar los mismos
EP2394667A1 (en) * 2010-06-10 2011-12-14 Laboratorios Del Dr. Esteve, S.A. Vectors and sequences for the treatment of diseases
UA115649C2 (uk) * 2010-06-25 2017-12-11 Шае Хюмен Дженетік Терапіс, Інк. Способи та композиції для доставки до цнс ідуронат-2-сульфатази
EP3546584B1 (en) * 2011-03-31 2024-02-14 University of Iowa Research Foundation Compositions for treating lysosmal storage disease (lsd)
US8609088B2 (en) * 2011-05-10 2013-12-17 Regents Of The University Of Minnesota Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases
US20130039888A1 (en) * 2011-06-08 2013-02-14 Nationwide Children's Hospital Inc. Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders
AU2012328682B2 (en) * 2011-10-27 2017-09-21 Sangamo Therapeutics, Inc. Methods and compositions for modification of the HPRT locus
BR112015028605A8 (pt) * 2013-05-15 2019-12-24 Univ Minnesota uso de uma composição e uso de um imunossupressor e uma composição
US10391184B2 (en) * 2013-07-26 2019-08-27 University Of Iowa Research Foundation Methods and compositions for treating brain diseases
MX2017014443A (es) * 2015-05-15 2018-08-01 Univ Minnesota Adeno-asociado para administracion terapeutica al sistema nervioso central.
IL309808A (en) * 2016-11-15 2024-02-01 Univ Minnesota A method to improve neurological function in MPSI and MPSII and other neurological disorders

Also Published As

Publication number Publication date
EP4000631A1 (en) 2022-05-25
RU2020125073A (ru) 2020-08-27
SI3294323T1 (sl) 2022-06-30
EP3294323A4 (en) 2019-01-16
US20180289839A1 (en) 2018-10-11
JP2021167332A (ja) 2021-10-21
MX2022012524A (es) 2022-11-16
AU2021266344A1 (en) 2021-12-09
JP2018515615A (ja) 2018-06-14
US20180071373A1 (en) 2018-03-15
ES2901766T3 (es) 2022-03-23
LT3294323T (lt) 2022-02-25
CA2986252A1 (en) 2016-11-24
HK1252871A1 (zh) 2019-06-06
DK3294323T3 (da) 2022-01-10
CN108367055A (zh) 2018-08-03
US20230226225A1 (en) 2023-07-20
RU2751952C2 (ru) 2021-07-21
KR102406615B1 (ko) 2022-06-08
PT3294323T (pt) 2022-01-06
US20220211875A1 (en) 2022-07-07
EP3294323B1 (en) 2021-10-13
PL3294323T3 (pl) 2022-06-20
KR20220082100A (ko) 2022-06-16
AU2016263119B2 (en) 2021-08-12
HK1256341A1 (zh) 2019-09-20
KR20180118508A (ko) 2018-10-31
US20210369871A1 (en) 2021-12-02
BR112017024519A2 (pt) 2018-07-24
RU2017143640A3 (hu) 2019-11-22
HRP20220050T1 (hr) 2022-10-14
JP2022137261A (ja) 2022-09-21
AU2016263119A1 (en) 2018-01-18
RU2017143640A (ru) 2019-06-17
EP3294323A1 (en) 2018-03-21
MX2017014443A (es) 2018-08-01
WO2016187017A1 (en) 2016-11-24
CY1125229T1 (el) 2023-06-09
RS63927B1 (sr) 2023-02-28

Similar Documents

Publication Publication Date Title
HK1256341A1 (zh) 用於治療性遞送到中樞神經系統的腺相關物
IL290823A (en) Pharmaceutical preparations for combination therapy
HK1258413A1 (zh) 遞送中樞神經系統(cns)靶向多核苷酸
IL268316B (en) Pharmaceutical preparations for combined treatment
HK1222767A1 (zh) 腺相關病毒介導基因轉移到中樞神經系統
GB201407896D0 (en) Insulin dosage proposal system
EP3023113A4 (en) DISPOSABLE DRUG DELIVERY SYSTEM WITHOUT CONDUCT
GB201506788D0 (en) Medicament delivery device
HK1252435A1 (zh) 用於聯合治療的vegfr-2靶向dna疫苗
HK1256875A1 (zh) 加强對大腦的藥物輸送
IL246874A0 (en) drug delivery system
GB2537639B (en) Medicament delivery device
GB2551453B (en) Nanocarrier delivery system for hydrophobic substances
IL256995A (en) Transdermal delivery system
IL256994A (en) Transdermal delivery system
GB201519321D0 (en) Drug delivery system
GB201517643D0 (en) Dosage form for melatonin
GB201506781D0 (en) Improved medicament delivery device
GB201506780D0 (en) Improved medicament delivery device
GB201413533D0 (en) Combination therapy for treating disorders of the vestibular system